SCHEMBL9904667

SCHEMBL9904667

CC[C@H]1NC(=O)N(c2ccc(Oc3ccc(C)c4c3C3(CC3)CO4)nc2)C1=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30939535 1.00
SCHEMBL19846867 1.00
SCHEMBL30939534 1.00
SCHEMBL9904821 0.90 MMP13 (0.30)
SCHEMBL30939606 0.90 MMP13 (0.30)
SCHEMBL17280422 0.90 MMP13 (0.30)
SCHEMBL19846866 0.89
SCHEMBL9904899 0.89
SCHEMBL18053272 0.88 TAS2R8 (0.31)
SCHEMBL21953282 0.88

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3386506-B1 MODULATORS OF KV3 CHANNELS TO TREAT PAIN AUTIFONY THERAPEUTICS LTD (GB) 2024-01-24 EP claimed
US-10835534-B2 Compounds AUTIFONY THERAPEUTICS LIMITED (GB) 2020-11-17 US claimed
US-10555945-B2 Compounds AUTIFONY THERAPEUTICS LIMITED (GB) 2020-02-11 US claimed
US-20190000849-A1 NOVEL COMPOUNDS AUTIFONY THERAPEUTICS LIMITED 2019-01-03 US claimed
US-20190000848-A1 MODULATORS OF KV3 CHANNELS TO TREAT PAIN AUTIFONY THERAPEUTICS LIMITED (GB) 2019-01-03 US claimed
EP-3386506-A1 MODULATORS OF KV3 CHANNELS TO TREAT PAIN Autifony Therapeutics Limited (GB) 2018-10-17 EP claimed
US-10098881-B2 Compounds AUTIFONY THERAPEUTICS LIMITED (GB) 2018-10-16 US claimed
US-20180036308-A1 NOVEL COMPOUNDS AUTIFONY SRL (IT) 2018-02-08 US claimed
WO-2017098254-A1 MODULATORS OF KV3 CHANNELS TO TREAT PAIN AUTIFONY THERAPEUTICS LIMITED (GB) 2017-06-15 WO claimed
US-20160317537-A1 NOVEL COMPOUNDS AUTIFONY SRL (IT) 2016-11-03 US claimed
EP-2788339-B1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS AUTIFONY THERAPEUTICS LTD (GB) 2016-03-09 EP claimed
US-9133175-B2 Compounds AUTIFONY THERAPEUTICS LIMITED (GB) 2015-09-15 US claimed
US-20140323508-A1 NOVEL COMPOUNDS AUTIFONY SRL (IT) 2014-10-30 US claimed
EP-2788339-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS Autifony Therapeutics Limited (GB) 2014-10-15 EP claimed
WO-2013083994-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS AUTIFONY THERAPEUTICS LIMITED (GB) 2013-06-13 WO claimed
US-20250017925-A1 MODULATORS OF KV3 CHANNELS TO TREAT PAIN AUTIFONY THERAPEUTICS LIMITED (GB) 2025-01-16 US disclosed
CN-118267386-A Modulators of KV3 channels for the treatment of pain 奥提芙尼治疗学有限公司 2024-07-02 CN disclosed
US-20130267510-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS AUTIFONY THERAPEUTICS LIMITED (GB) 2013-10-10 US disclosed
WO-2013083994-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS AUTIFONY THERAPEUTICS LIMITED (GB) 2013-06-13 WO disclosed
WO-2012076877-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS AUTIFONY THERAPEUTICS LIMITED (GB) 2012-06-14 WO disclosed